DryFlowEx TBNK+ MonoDR 9-color

TBNK immunophenotyping remains one of the most essential and widely used flow-cytometric assays in clinical diagnostics. Its strong standardization and fast turnaround make it the first-line tool for assessing immune competence and supporting decision-making in immunology, hematology, infectious diseases, and even reproductive medicine.
In clinical practice, TBNK provides crucial insights for the evaluation of immunodeficiencies, monitoring of biologic and immunomodulatory therapies, and long-term management of HIV patients. Hematology laboratories rely on TBNK to help distinguish reactive from clonal lymphocyte populations, assess lymphopenia, and monitor immune reconstitution after chemotherapy or stem-cell transplantation. Increasingly, TBNK panels are also used in reproductive medicine, where the balance of T-, B-, and NK-cell subsets can support personalized treatment strategies.
 

We are now launching a next-generation solution in the form of a new DryFlowEx TBNK+ product line which exceeds the capabilities of conventional 6-color TBNK panels. The first product introduced is now DryFlowEx TBNK+ MonoDR 9-color (RUO) with catalog number ED7815.
The extended 9-color design of this product increases both analytical depth and clinical relevance. Since this is a dried version of immunoreagents in single-test tubes, the product is also designed for greater efficiency of the workflow in the clinical laboratory.

Key advantages of the DryFlowEx TBNK+ MonoDR 9-color (RUO) over classic TBNK include:

1. Extended clinical insight from a single tube, minimizing the need for additional panels and reducing hands-on time.
2. Higher workflow efficiency with greater information density.
3. Detection of additional clinically meaningful subpopulations allowing:
   • Immunomonitoring of HLA-DR expression mainly on CD3+ T cells (Figure 1), where an increased value may indicate recent immune activation (e.g., viral or bacterial infection, some autoimmune diseases)
   • Simultaneously immunomonitoring of HLA-DR expression on monocytes (Figure 2), a well-established marker whose lower expression is associated with sepsis, systemic inflammation, and immunoparalysis
   • The separation of antibodies against CD16 and CD56 markers into different fluorochromes allows the identification of the CD56dimCD16+ vs. CD56brightCD16dim(-) NK cell subsets (Figure 3), important for identifying NK-cell dysregulation seen in autoimmune conditions, viral infections, or implantation failure
   • The concurrent inclusion of an antibody against the monocyte marker CD14 and an antibody against CD16 in the fluorochrome itself allows differentiation of monocytes into classical, intermediate and non-classical subsets (Figure 4) which can altered in various diseases, making them potential biomarkers for disease severity, progression, and treatment response

Product Description:

• TBNK+ MonoDR 9-color ED7815-1 (10 pouches). Each pouch consists of 5 capped single-use tubes containing premixed combination of fluorochromelabeled reagents dried with the stabilizing ingredients as a layer at bottom of the test tubes (12 x 75 mm), see Table 1.
• TBNK+ MonoDR 9-color Compensation Set ED7815-2 (1 pouch) containing 9 capped single-use tubes, each containing single fluorochrome-labeled reagent (see Table 1) dried with the stabilizing ingredients as a layer at the bottom of the tube (12 x 75 mm).

Tab.1: Description of the active ingredients

Antigen	Flurochrome	Clone	Isotype
CD45	Pacific Orange™	MEM-28	IgG1
CD3	FITC	TB3	IgG2b
CD4	APC-Cy™7	MEM-241	IgG1
CD8	PerCP	LT8	IgG1
CD16	Alexa Fluor® 700	3G8	IgG1
CD19	PE-Cy™7	LT19	IgG1
CD56	APC	LT56	IgG2a
CD14	PE	MEM-15	IgG1
HLA-DR	Pacific Blue™	L243	IgG2a kappa

Do you have any questions? Let us know by e-mail or use our FORM!
Contact: info@exbio.cz